Literature DB >> 15547539

Prophylactic antibiotics for non-laboring patients with intact membranes undergoing cesarean delivery: an economic analysis.

David Chelmow1, Michael Hennesy, Edward G Evantash.   

Abstract

OBJECTIVE: We conducted an economic analysis of prophylactic antibiotic administration for elective cesarean delivery. STUDY
DESIGN: We created a decision tree comparing the use of prophylactic antibiotics (cefazolin 1 gm intravenous) with no antibiotic use. We modeled the potential for anaphylaxis, and included outcomes of fever and endometritis. Outcome probabilities and effectiveness of antibiotic administration were derived from published sources. Costs are 2001 estimates derived from our hospital's accounting system. Sensitivity analyses were performed over the range of actual patient costs and 95% CI of the risk and probability estimates.
RESULTS: Cost of an uncomplicated elective cesarean delivery was $1638.57. Fever evaluation added $125.91. Elective procedure complicated by endometritis cost $2327.29. Cefazolin administration cost $1.01. The following estimates were used: relative risk (RR) of endometritis with antibiotics was 0.18 (95% CI 0.07-0.45), fever 0.47 (95% CI 0.32-0.68), risk of endometritis without prophylaxis 4.8% (95% CI 0.9%-43%), and fever without prophylaxis 14.4% (95% CI 4%-33%). Cost of an average case without prophylaxis was $1683.72; prophylaxis reduced this to $1653.06. Sensitivity analysis over the ranges above still yielded cost savings.
CONCLUSION: Administration of prophylactic antibiotics for elective cesarean delivery reduced costs by $30.66 per case, approximately 2% of the total cost. Prophylactic antibiotic administration results in cost savings for elective cesarean delivery.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15547539     DOI: 10.1016/j.ajog.2004.03.079

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

Review 1.  [Complications associated with inguinal orchiectomy and scrotal orchiectomy].

Authors:  P Anheuser; J Kranz; J Will; K P Dieckmann
Journal:  Urologe A       Date:  2014-05       Impact factor: 0.639

2.  Economic Evaluation of Adjunctive Azithromycin Prophylaxis for Cesarean Delivery.

Authors:  Lorie M Harper; Meredith Kilgore; Jeff M Szychowski; William W Andrews; Alan T N Tita
Journal:  Obstet Gynecol       Date:  2017-08       Impact factor: 7.661

Review 3.  Current debate on the use of antibiotic prophylaxis for caesarean section.

Authors:  R F Lamont; J D Sobel; J P Kusanovic; E Vaisbuch; S Mazaki-Tovi; S K Kim; N Uldbjerg; R Romero
Journal:  BJOG       Date:  2011-01       Impact factor: 6.531

Review 4.  Emerging concepts in antibiotic prophylaxis for cesarean delivery: a systematic review.

Authors:  Alan T N Tita; Dwight J Rouse; Sean Blackwell; George R Saade; Catherine Y Spong; William W Andrews
Journal:  Obstet Gynecol       Date:  2009-03       Impact factor: 7.661

5.  Attributable costs of surgical site infection and endometritis after low transverse cesarean delivery.

Authors:  Margaret A Olsen; Anne M Butler; Denise M Willers; Gilad A Gross; Barton H Hamilton; Victoria J Fraser
Journal:  Infect Control Hosp Epidemiol       Date:  2010-03       Impact factor: 3.254

6.  Cost-effectiveness of antibiotic prophylaxis in elective cesarean section.

Authors:  Markus H Jansson; Yang Cao; Kerstin Nilsson; Per-Göran Larsson; Lars Hagberg
Journal:  Cost Eff Resour Alloc       Date:  2018-12-18

7.  Perioperative antibiotic prophylaxis for nonlaboring cesarean delivery.

Authors:  Mara J Dinsmoor; Sharon Gilbert; Mark B Landon; Dwight J Rouse; Catherine Y Spong; Michael W Varner; Steve N Caritis; Ronald J Wapner; Yoram Sorokin; Menachem Miodovnik; Mary J O'Sullivan; Baha M Sibai; Oded Langer
Journal:  Obstet Gynecol       Date:  2009-10       Impact factor: 7.661

Review 8.  Antibiotic use and misuse during pregnancy and delivery: benefits and risks.

Authors:  Begoña Martinez de Tejada
Journal:  Int J Environ Res Public Health       Date:  2014-08-07       Impact factor: 3.390

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.